Helping You Build Wealth With Honest Research
Since 1996. Try Now

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Banks, auto drag the markets down
Tue, 15 Dec 02:30 pm

Despite persistent efforts to pare the losses witnessed during the early hours of trade today, the Indian stock markets nosedived below the dotted line during the previous two hours of the trade. Currently stocks from the banking, auto and capital goods sectors are dragging the markets lower, while stocks from the healthcare, FMCG, metal and IT sectors are trading in the green.

The BSE Sensex and NSE Nifty are trading lower by 137 and 49 points respectively. BSE Midcap and BSE Smallcap are trading down by 0.8% and 0.6% respectively.The rupee is trading at 48.60 to the Dollar.

According to a leading business daily, the Tata group of companies is planning to revamp its position in the hospitality segment of budget hotels. It plans to build as many as 50 budget hotels in its no frills segment - Ginger, across India in the next four years. It may be noted that Tata Group's hospitality arm Indian Hotels Company already has 20 Ginger hotels across the country. With an average of 100 rooms per hotel, the planned capex will add 5000 rooms to the inventory during the next four years. The company has already started work in the tier-2 cities like Surat, Indore, Tripur and Lucknow. The conglomerate is seeing a pickup in the inbound tourist traffic. The estimated demand for the new upscale rooms in major Indian cities will swell up to 25,000 by 2010. The same in the mid scale and budget segment is expected to stand at around 18,000.

As per a leading business daily, GSK Pharma will forge supply partnerships with Indian and African generics companies as a strategy to expand its business in the emerging markets. The company aims at becoming a major player in these markets through a broad portfolio of branded generics. The company expects that in markets like India only 10-15% of pharma market will account for patented medicines even after a decade, so it needs to focus on generics as a growth driver in these markets. We believe such agreements will help Indian healthcare companies like DRL and Sun Pharma to gain a foothold in the branded generics segment.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Banks, auto drag the markets down". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Agora Research Private Limited.

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Agora Research Private Limited (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.